Heyworth Benton E, Lee Jonathan H, Kim Paul D, Lipton Carter B, Strauch Robert J, Rosenwasser Melvin P
Columbia University College of Physicians & Surgeons, New York, NY 10032, USA.
J Hand Surg Am. 2008 Jan;33(1):40-8. doi: 10.1016/j.jhsa.2007.10.009.
Conservative, nonsurgical therapies for basal joint osteoarthritis, such as thumb spica splinting and intra-articular corticosteroid injections, remain the mainstays for symptomatic treatment. This study compares intra-articular hylan, corticosteroid, and placebo injections with regard to pain relief, strength, symptom improvement, and metrics of manual function in a randomized, controlled, double-blinded study.
Sixty patients with basal joint arthritis were randomized to receive 2 intra-articular hylan injections 1 week apart, 1 placebo injection followed by 1 corticosteroid injection 1 week later, or 2 placebo injections 1 week apart. Patients were evaluated at 2, 4, 12, and 26 weeks and assessed with Visual Analog Scale pain scores, strength measures, difference scores, Disabilities of the Arm, Shoulder, and Hand (DASH) scores, and range of motion measurements.
All groups reported pain relief at 2 weeks. The steroid and placebo groups had significantly less pain at week 4 compared with baseline, but this effect disappeared by week 12. Only hylan injections continued to provide pain relief at 12 and 26 weeks compared with baseline. There were no significant differences in pain between groups at any time. At 12 and 26 weeks, the hylan group had improved grip strength compared with baseline, whereas the steroid and placebo groups were weaker. At 4 weeks, the steroid group reported in the difference score a greater improvement in symptoms (68%) compared with the hylan (44%) and placebo (50%) groups. Whereas at 26 weeks the hylan group reported the largest improvement in symptoms (68%), this was not statistically different from the placebo (47%) and steroid (58%) groups. There were no significant differences in Disabilities of the Arm, Shoulder, and Hand scores or range of motion among the groups. There were no complications from any injection.
There were no statistically significant differences among hylan, steroid, and placebo injections for most of the outcome measures at any of the follow-up time points. However, based on the durable relief of pain, improved grip strength, and the long-term improvement in symptoms compared with preinjection values, hylan injections should be considered in the management of basal joint arthritis of the thumb.
TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic I.
对于拇指腕掌关节骨关节炎,保守的非手术治疗方法,如拇指人字形夹板固定和关节内注射皮质类固醇,仍然是症状治疗的主要手段。本研究在一项随机、对照、双盲研究中,比较关节内注射透明质烷、皮质类固醇和安慰剂在缓解疼痛、增强力量、改善症状以及手部功能指标方面的效果。
60例拇指腕掌关节关节炎患者被随机分为三组,分别接受:相隔1周的2次关节内透明质烷注射;1次安慰剂注射,1周后再注射1次皮质类固醇;或相隔1周的2次安慰剂注射。在第2、4、12和26周对患者进行评估,采用视觉模拟评分法评估疼痛程度、测量力量、计算差异分数、使用手臂、肩部和手部功能障碍(DASH)评分以及测量活动范围。
所有组在第2周时均报告疼痛有所缓解。与基线相比,类固醇组和安慰剂组在第4周时疼痛明显减轻,但这种效果在第12周时消失。与基线相比,只有透明质烷注射在第12周和第26周时仍能持续缓解疼痛。在任何时间点,各组之间的疼痛均无显著差异。在第12周和第26周时,与基线相比,透明质烷组的握力有所改善,而类固醇组和安慰剂组则较弱。在第4周时,类固醇组报告的症状差异分数改善率(68%)高于透明质烷组(44%)和安慰剂组(50%)。而在第26周时,透明质烷组报告的症状改善率最高(68%),但与安慰剂组(47%)和类固醇组(58%)相比,差异无统计学意义。各组之间的手臂、肩部和手部功能障碍评分或活动范围均无显著差异。所有注射均未出现并发症。
在任何随访时间点,对于大多数结局指标,透明质烷、类固醇和安慰剂注射之间均无统计学显著差异。然而,基于与注射前相比疼痛的持久缓解、握力的改善以及症状的长期改善,在拇指腕掌关节关节炎的治疗中应考虑使用透明质烷注射。
研究类型/证据水平:治疗性I级